Drug
Vly 686
Vly 686: highest development phase Phase 2, developed by Vanda Pharmaceuticals. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Vanda Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| VLY-686 NCT02004041 | Phase 2 | Treatment-resistant Pruritus Associated With Atopic Dermatitis |
| VLY-686 (Tradipitant) NCT02970968 | Phase 2 | Gastroparesis |
| VLY-686 NCT01919944 | Phase 1 | Pruritus |
Latest
No recent events.
Follow Vly 686 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.